semaglutide death reduces risk of all-cause Semaglutide and Cardiovascular Outcomes in

Cosmos Study October 14, 2025 Dual-Team Study Team A:Kersten Bartelt, RNEric Barkley Team B:Joel Jones, PharmDJoe Deckert, PhD Key Findings Among non-diabetic patients without chronic kidney disease (CKD), there was a minimal increase of 0.01 mg/dL to 0.02 mg/dL in serum creatinine in the months following initiation of semaglutide, liraglutide, or tirzepatide

Some products are legitimate options for the right person

Comparing Other Medical Weight Loss Options with GLP-1 Agonist Treatments While these medications offer various mechanisms of action for weight loss, GLP-1 agonists like Ozempic and Wegovy have the advantage of directly targeting appetite regulation and glucose metabolism, making them highly effective options for individuals with obesity and type 2 diabetes

Severe small bowel dilation